by telrheum | Jun 16, 2024 | Biologic Therapy, JAK Inhibitor, systemic juvenile idiopathic arthritis
Background: Systemic juvenile idiopathic arthritis (sJIA) is a severe form of arthritis in children that can lead to serious complications like macrophage activation syndrome (MAS) and lung disease. Even with current treatments like steroids and IL-1 inhibitors, some...
by telrheum | Jun 16, 2024 | Degenerative Arthritis, Arthritis Supplements, Dietary Changes, Osteoarthritis
Background: The “Plants for Joints” (PFJ) program is a 16-week lifestyle intervention aimed at people with osteoarthritis (OA) of the hip or knee and metabolic syndrome. The program includes a whole-food, plant-based diet, physical activity, and stress management....
by telrheum | Jun 15, 2024 | Osteoarthritis, Antibody Therapy, Gene Therapy
Background: This study aimed to evaluate the safety and effectiveness of XT-150, a new gene therapy, for treating moderate to severe pain caused by osteoarthritis (OA) of the knee. XT-150 is designed to produce a special version of the anti-inflammatory protein...
by telrheum | Jun 15, 2024 | Systemic Sclerosis, Autoimmune Diseases, Calcinosis
Background: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases that primarily affect the muscles, causing inflammation. Calcinosis cutis, a condition where calcium deposits form in the skin, often accompanies connective tissue diseases, leading to...
by telrheum | May 27, 2024 | Autoimmune Diseases, Biologic Therapy, IgG4-Related Diseases, JAK Inhibitor
The article “Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients” presents a study conducted at Peking University People’s Hospital. The study aimed to evaluate the effectiveness and safety of tofacitinib, a Janus...